Eli Lilly Cancer Drug fails during clinical trial
Eli Lilly and Co has reported failure of its experimental lung cancer drug for late-stage trial. During the current trial, Lilly was testing Verzenio in patients with advanced non-small cell lung cancer with mutation of the KRAS gene. The company has shared limited data about the drug trial and informed that the overall survival rate among patients in the trial didn’t improve. Eli Lilly has suffered two other setbacks earlier this year.
The company faced U.S. FDA rejection rheumatoid arthritis drug in April. The company has witnessed decline in stock valuation as well. After the new, Lilly stock was down by nearly 3 percent during early trading session. With an aim to cut costs, Lilly reduced its workforce by 8 percent last month. The company informed that reduction in workforce would save $500 million each year.
Lilly informed, “Verzenio, however, showed some evidence of improvement in the secondary goals such as progression-free survival in patients and overall response rate.”
Verzenio has been approved by FDA for advanced stage breast cancer last month.
In November last year, the company dropped an experimental Alzheimer’s treatment after the results weren’t encouraging.
Machine Tools Market report provides throughout analysis of the potential of Machine Tools Market and provides statistics and information on market size, shares and growth fa
Air Pumps Market analysis report speaks about the manufacturing process.
Fly Reel Market Report provides information about Fly Reel industry including Market overview, Emerging Market Trends, Market Demand, Segmentation, Investment Strategies for
Cycling Sunglass Market report is to help the user understand the market in terms of its classification, segmentation, market potential, influential trends,
Heat Exchanger for Chemical Process Market Report provides current scenario, opportunities, restraints, drivers and the growth forecasts of the market for 2017-2022.
Flat Panel Cleaning Equipment Market Report provides current scenario, opportunities, restraints, drivers and the growth forecasts of the market for 2018-2022.